Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24146439 | 0.94 | SIRT2 (0.46) | — | |
| SCHEMBL25867315 | 0.94 | CCKBR (0.50) | CCKBRREN | |
| SCHEMBL25865433 | 0.91 | NPY4R (0.52) | — | |
| SCHEMBL24146441 | 0.90 | OPRM1 (0.49) | — | |
| SCHEMBL19862397 | 0.90 | NPY4R (0.52) | CCKBRREN | |
| SCHEMBL18048887 | 0.90 | NPY4R (0.52) | CCKBRREN | |
| SCHEMBL19862098 | 0.90 | NPY4R (0.52) | CCKBRREN | |
| SCHEMBL19862399 | 0.90 | NPY4R (0.52) | CCKBRREN | |
| SCHEMBL21627105 | 0.89 | CCKBR (0.53) | CCKBRREN | |
| SCHEMBL16862457 | 0.89 | CCKBR (0.53) | CCKBRREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4168424-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | CCKBR 1024/4885REN 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.